# Dassault Systemes BIOVIA

BIOVIA ONE Lab — 企业级生物制药 LIMS.

Source: https://cn.bioecon.ru/companies/biovia/
Updated: 2026-06-24

- 国家: France

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 融资 | Dassault Systèmes未单独披露BIOVIA品牌的融资轮次，因其为上市公司Dassault Systèmes旗下的运营品牌。 | https://investor.3ds.com/static-files/dc4d4da1-59c3-45cf-86db-7488e2fd0119, https://investor.3ds.com/static-files/f345f4ee-bb0a-489e-8c1d-f43f18f47506, https://www.3ds.com/newsroom/press-releases/dassault-systemes-solid-q2-results-and-confirming-full-year-objectives-delivering-ai-native-solutions-and-expanding-life-sciences-acquisition-arisglobal, https://www.itnewsonline.com/GlobeNewswire/Dassault-Systmes-reports-first-quarter-2026-results-in-line-with-objectives-and-confirms-full-year-outlook/120503 |
| 总部 | 美国加利福尼亚州圣地亚哥 | https://www.3ds.com/assets/invest/2025-04/biovia-quality-statement.pdf |
| 认证 | ISO 9001:2015（3DEXPERIENCE平台云应用）、ISO/IEC 27001:2013（ScienceCloud） | https://blog.3ds.com/brands/biovia/gxp-compliance-in-the-cloud/, https://discover.3ds.com/biovia-unified-scientific-innovation, https://intuitionlabs.ai/articles/qumas-edms-life-sciences-guide, https://www.3ds.com/assets/invest/2025-04/biovia-quality-statement.pdf, https://www.3ds.com/products/biovia/regulatory-management |
| 监管批准 | 产品按FDA 21 CFR Part 11、GxP及附录11的合规要求设计。 | https://blog.3ds.com/brands/biovia/gxp-compliance-in-the-cloud/, https://discover.3ds.com/biovia-unified-scientific-innovation, https://intuitionlabs.ai/articles/qumas-edms-life-sciences-guide, https://www.3ds.com/assets/invest/2025-04/biovia-quality-statement.pdf |
| 员工人数 | 截至2025年12月31日，Dassault Systèmes员工总数为25,967人。BIOVIA的单独人数未予披露。 [中等置信度] | https://investor.3ds.com/news-releases/news-release-details/dassault-systemes-q2-well-aligned-objectives-reaffirming-2025, https://investor.3ds.com/news-releases/news-release-details/dassault-systemes-q4-revenue-growth-1-solid-operating-margin-and, https://investor.3ds.com/news-releases/news-release-details/dassault-systemes-solid-start-year-strong-subscription-growth, https://investor.3ds.com/static-files/f345f4ee-bb0a-489e-8c1d-f43f18f47506, https://www.appsruntheworld.com/customers-database/products/view/dassault-biovia |
| 营收 | 生命科学软件收入（含MEDIDATA与BIOVIA）2025全年为€10.8亿。BIOVIA收入未单独披露。 | https://investor.3ds.com/news-releases/news-release-details/dassault-systemes-q2-well-aligned-objectives-reaffirming-2025, https://investor.3ds.com/news-releases/news-release-details/dassault-systemes-q4-revenue-growth-1-solid-operating-margin-and, https://investor.3ds.com/static-files/f345f4ee-bb0a-489e-8c1d-f43f18f47506, https://live.euronext.com/sites/default/files/esg_document_files/2026-06/064315_3DS_CORPORATE%20REPORT_2025_1_2026-06-17_10%3A46.pdf |

独立来源: 3ds.com, appsruntheworld.com, blog.3ds.com, discover.3ds.com, intuitionlabs.ai, investor.3ds.com, itnewsonline.com, live.euronext.com

## 技术

- [实验室执行系统（LES）](https://cn.bioecon.ru/technology/laboratory-execution-systems/)
- [生物制造 LIMS/ELN](https://cn.bioecon.ru/technology/lims-eln-bioproduction/)